Merck (MRK) is reportedly gearing up to acquire approximately 10% of the shares in the upcoming initial public offering (IPO) of Eikon Therapeutics. According to sources, the pharmaceutical company intends to inject around $30 million into Eikon. This strategic investment aligns with Merck’s broader efforts to expand its portfolio and engage in innovative therapeutic ventures.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.